Pin your most used calculators here by clicking the star in the dropdown.
Prosigna / PAM50 Interpreter
Clinical Context & Background
The Prosigna (PAM50) gene signature provides a Risk of Recurrence (ROR) score (0-100) for postmenopausal women with HR+, HER2-, early-stage breast cancer. It assigns an intrinsic subtype (Luminal A/B, HER2-E, Basal-like) and stratifies the 10-year risk of distant recurrence to guide adjuvant therapy decisions.
Formula Logic
Interpretation of ROR Score (0-100) based on Nodal Status.Reference Data
| Nodal Status | ROR Range | Risk Category | 10y Distant Recurrence |
|---|---|---|---|
| Node Negative | 0 - 40 | Low | < 10% |
| Node Negative | 41 - 60 | Intermediate | Varies |
| Node Negative | 61 - 100 | High | > 20% |
| Node Positive (1-3) | 0 - 15 | Low | < 10% |
| Node Positive (1-3) | 16 - 40 | Intermediate | Varies |
| Node Positive (1-3) | 41 - 100 | High | > 20% |
Evidence-based oncology decision support. Verify with clinical guidelines.